Pharmaceutical Technology Europe, May 1, 2010 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharmaceutical Technology Europe, May 1, 2010
Special Feature
Understanding powder behaviour
By Tim Freeman
The needs of the pharmaceutical industry for powder testing technologies are changing, primarily for two reasons.
When and why should the pharmaceutical industry use NIR chemical imaging?
By Janie Dubois
The author assesses the power and limitations of NIR chemical imaging and its future.
Bioanalysis: hurdles and hopes
By Patrick Bennett
Bioanalysis has migrated from a very general vocation to one that requires more specialization, particularly in GLP applications.
Innovations in dissolution testing
By Tony Copley
Advances in dissolution testing technology have been one of the biggest breakthroughs in solid dosage form testing over the last decade.
Do emerging markets provide the answer to the pharmaceutical industry?
By Luigi G. Martini , Sandy Macrae
The emerging markets represent an attractive investment opportunity for the pharmaceutical industry because of the countries' growing economies and unmet medical needs.
REACH: has the cloud of confusion cleared?
By Malcolm Pollard
The pharmaceutical industry must understand its responsibilities to improve the safety of chemicals as defined by the REACH initiative.
Change management: common failures and a checklist for improvement
By Henrik Johanning , John V. Lee , Christian Hemmingsen
Though the pharma industry has improved its change management processes, there are still opportunities for improvement.
Obtaining simultaneous multiple dissolution profiles of solid oral dosage formulations
By Ana Rita Pires , D. López Malo , J. Martínez Calatayud
Testing the dissolution rates of a pharmaceutical formulation (also known as in vitro availability) aids drug quality control and is a compulsory requirement of the British, European and US pharmacopoeias.
Ask the Expert
The possibilities and challenges of spray drying
By Henrik Schwartzbach
Why spray drying processes offer a range of particle engineering possibilities.
Outsourcing Review
The Lilly Way
By Jim Miller
Lilly faces up to the new realities of the bio/pharmaceutical industry by embracing outsourcing.
Change is in the air for the European Clinical Trials Directive
By Faiz Kermani
Though many advantages are associated with the European Clinical Trials Directive, complexities have emerged since its introduction in 2004. Since 2007, efforts have been made to raise the issues and address the negative impact of the Directive.
A round up of news from across the globe.
Editor's Comment
What do you think?
By Fedra Pavlou
Over the last few months, we have been publishing a series of special features, which have sought to provide you with an overall view of current challenges, innovations and trends in niche pockets of the pharmaceutical industry.


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here